Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | AMG 420 BiTE for R/R multiple myeloma

Thierry Facon • 11 Dec 2018
ASH 2018
Multiple Myeloma AMG 420 Antibodies

The AMG 420 bi-specific T-cell engager (BiTE) therapy which targets the anti–B-cell maturation antigen (BCMA) is now being tested in relapsed/refractory multiple myeloma (MM). Here, Thierry Facon, MD, of Lille University Hospital, Lille, France, also discusses the latest data from the Phase I dose-escalation study (NCT02514239) assessing the safety, tolerability and anti‑tumor activity of AMG 420, a CD3 BiTE. Dr Facon presented the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA,

More from Thierry Facon

5:09
Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates
Thierry Facon • 14 Jun 2019
3:23
Upcoming updates in multiple myeloma
Thierry Facon • 14 Jun 2019
2:19
Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
Thierry Facon • 11 Dec 2018
2:19
MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM
Thierry Facon • 6 Dec 2018

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals